Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan.
about
Atherosclerosis as Extrahepatic Manifestation of Chronic Infection with Hepatitis C VirusExtrahepatic manifestations of chronic hepatitis C virus infectionChronic hepatitis C: This and the new era of treatmentHepatitis C virus infection and risk of stroke: a systematic review and meta-analysisHepato-cardiac disordersHepatitis C virus (HCV) genotypes distribution: an epidemiological up-date in EuropeFatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIVChronic hepatitis C virus infection and neurological and psychiatric disorders: an overviewHepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis.Management of Neurologic Manifestations in Patients with Liver Disease.Stroke in HIV-infected individuals with and without HCV coinfection in Spain in the combination antiretroviral therapy era.Distinct patterns of the lipid alterations between genotype 1 and 2 chronic hepatitis C patients after viral clearanceIncidence rates of tuberculosis in chronic hepatitis C infected patients with or without interferon based therapy: a population-based cohort study in Taiwan.A Taiwanese Nationwide Cohort Study Shows Interferon-Based Therapy for Chronic Hepatitis C Reduces the Risk of Chronic Kidney DiseaseAssociation of Rheumatoid Arthritis and Hepatitis B Infection: A Nationwide Nested Case-Control Study From 1999 to 2009 in TaiwanInterferon-Based Treatment of Hepatitis C Virus Infection Reduces All-Cause Mortality in Patients With End-Stage Renal Disease: An 8-Year Nationwide Cohort Study in Taiwan.New insights into HCV-related rheumatologic disorders: A review.Hepatitis C virus and cardiovascular: A review.Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanismsHepatitis C in 2013: HCV causes systemic disorders that can be cured.Cardiovascular diseases and HCV infection: a simple association or more?The impact of hepatitis C burden: an evidence-based approach.Atherosclerosis as a possible extrahepatic manifestation of chronic hepatitis C virus infection.Extrahepatic manifestations in chronic hepatitis C virus carriers.Why do I treat my patients with mild hepatitis C?Chronic hepatitis C virus infection, a new cardiovascular risk factor?Eradication of hepatitis C virus and non-liver-related non-acquired immune deficiency syndrome-related events in human immunodeficiency virus/hepatitis C virus coinfection.Impact of hepatitis C virus therapy on metabolism and public health.Association between interferon use and reduced metabolic and vascular complications among patients with hepatitis C.Management of Cirrhotic Patients After Successful HCV Eradication.Haematuria is not a risk factor of hypertension or renal impairment in patients with haemophilia.Hepatitis C viral infection increases the risk of lymphoid-neoplasms: A population-based cohort study.Extrahepatic Complications of Hepatitis C Virus Infection in HIV and the Impact of Successful Antiviral Treatment.Risk of Cardiovascular Disease Due to Chronic Hepatitis C Infection: A Review.Hepatitis C virus cure does not impact kidney function decline in HIV co-infected patients.The Unravelled Link between Chronic Kidney Disease and Hepatitis C Infection
P2860
Q26765245-A17F1049-5200-45FA-8BE2-BA8A3CF2058CQ26767084-F82E2650-21FA-47A9-AFA5-BBFC683DC19CQ26775011-0865C41D-8454-4AF5-861A-70AD7FE3DA24Q26863156-2EE3EDAE-B0C4-436B-9AB2-A1DA81C1B68AQ26997114-677592F7-0FB5-4C5C-922A-9D86879F5DD6Q28079580-3B83F24D-69FC-4E1C-B8D5-1CBA9BF9CB83Q28079826-E50A6E45-CA12-46BA-B1C8-7A0444E47087Q28082212-40596AFF-4050-4300-A6DF-0B9A30D7212CQ30360538-D78CDAAF-C48A-4628-8311-D48FD8A12D02Q31108752-E7715833-BF0B-41D4-973D-87C78DB03DC8Q33803319-80DAF83B-E18C-41C8-B95D-58DAAC5D91C3Q34046758-370E3F40-1B1F-4312-87B3-AADCB5668773Q35016345-F8E120BE-F6FE-40ED-9EB0-CE390A4D6E9AQ36195230-F23727D4-9D2D-474B-9FE8-9278575FFEE3Q36891861-D3962868-339B-4255-96A9-1249602D3219Q37328650-19864998-48CD-47C2-A0E0-F62060203C94Q37610871-86D0767B-10FC-451D-8112-C8EFF082F6A1Q37610905-3B3367BC-387F-4173-BCCA-A27AA6AEE6C9Q37682486-6FAFDE1F-2144-435B-A03D-8F2F51039C9BQ38166180-742AC035-505F-452F-ABAF-6DB9B2F23C3BQ38167953-47EE9329-3A0E-4EC8-B6F0-9EF95A9CA9DAQ38181631-2ACD20DE-8F83-4F7A-AFDC-CEA34486FBF9Q38276377-9505DE29-DD13-480C-8034-B64A94AA8E29Q38388423-F7DEB2E8-1260-44DA-9CE9-45887FA5AA74Q38685564-9757AF78-CA76-4676-BD03-2FF80BA25EAFQ38695606-83C7108D-1943-4EC3-9DF8-BAD85EB55C0AQ39008634-97A12C4C-9DA2-4E08-B364-6EABAD57A136Q39040729-96C8D1D9-E6B3-440D-A381-C5D4F75681C4Q39146830-470FF34A-8416-49DC-9880-1213911BDEB5Q39260393-1E82ACB2-C08F-44D3-8CAF-226B151631C8Q39876322-4463BBBD-AE9B-4DA8-B824-9895311E8410Q40216845-F62A5E22-A357-4F17-9F97-9BCD587213D4Q40341541-8C3CD4A2-A105-4863-9F30-7B81644F83DBQ47169604-A0527966-8AAD-4AE3-AA59-2280A4C12CD5Q47549008-05B91E0C-DD43-4AF9-B9BE-7C7214822D18Q59072614-A79F0510-08C8-4813-AFB7-65D11B071B5C
P2860
Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Interferon-based therapy reduc ...... -based cohort study in Taiwan.
@en
Interferon-based therapy reduc ...... -based cohort study in Taiwan.
@nl
type
label
Interferon-based therapy reduc ...... -based cohort study in Taiwan.
@en
Interferon-based therapy reduc ...... -based cohort study in Taiwan.
@nl
prefLabel
Interferon-based therapy reduc ...... -based cohort study in Taiwan.
@en
Interferon-based therapy reduc ...... -based cohort study in Taiwan.
@nl
P2093
P2860
P356
P1476
Interferon-based therapy reduc ...... n-based cohort study in Taiwan
@en
P2093
P2860
P304
P356
10.1111/APT.12391
P407
P577
2013-06-26T00:00:00Z